华东医药子公司获得新型抗癌药物临床试验批准

本文如何被排名

Signal score

0 / 100

Composite score across the factors below. Higher = stronger signal that this story matters right now.

Newsworthiness bucket

Tool

新型药物的临床试验批准。[lever_c_demoted from research: ic=1 ai=0.4]

Source corroboration

Single-source cluster

Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.

Topics

product, other

Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.

AI-industry relevance

Standard

On-topic for AI-industry coverage; kept in the public index.

Story freshness

97 days old

Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。